Radioimmunoscintigraphy of Breast Cancer

Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy

Radioimmunoscintigraphy of Breast Tumor Xenografts in Mouse Model by 99mTc Direct Radiolabeling of a Monoclonal Antibody PR81

Introduction: The radioimmunoscintigraphy (RIS) has found widespread clinical applications in  tumor  diagnosis.  Human  epithelial  mucin,  MUC1,  is  commonly  over  expressed  in  adenocarcinoma including 80% of breast cancers and represents a useful target for RIS. The PR81  is  a  new  murine  anti-MUC1  monoclonal  antibody  that  was  found  to  react  with  the  membrane  extracts of se...

Journal of Immunology and Serum Biology

Breast cancer has become one of the leading causes of death in women today. Many researches are ongoing to develop more effective imaging methods for early diagnosis of breast cancer. The application of nuclear medicine techniques to study patients with breast cancer has recently raised its profile, particularly in the investigation ‘indeterminate mammographic lesions’. Radio labeled monoclonal...

Production and Quality Control of [67Ga]-DOTA-trastuzumab for Radioimmunoscintigraphy

Breast cancer radioimmunoscintigraphy targeting HER2/neu expression is a growing fieldof work in nuclear medicine research. In this study, trastuzumab was successively labeledwith [67Ga] GaCl3 after conjugation with DOTA-NHS-ester.The conjugates were purified by molecular filtration, the average number ofDOTA conjugated per mAb was calculated and total concentration was determined byspectrophot...

99mTc Direct radiolabeling of PR81, a new anti-MUC1 monoclonal antibody for radioimmunoscintigraphy

  Introduction: Monoclonal antibodies labeled mainly with 99mTc are being widely used as imaging agents in nuclear medicine. Recently PR81 was introduced as a new murine anti-MUC1 MAb against human breast carcinoma. This antibody reacts with the tandem repeat of 20-mer peptide of protein backbone, and is of IgG1 class, with an affinity of 2.19×10-8 M-1. Due to high sp...